Medical Device U.S. Agent, Official Correspondent, and Initial Importer Roles

Introduction

Foreign medical device manufacturers often discover too late that their U.S. contacts are not interchangeable. In FDA device registration, the U.S. Agent, official correspondent, and initial importer sit in different parts of the workflow: one is the FDA-facing U.S. contact for a foreign establishment, one controls registration and listing communications inside FDA systems, and one is the U.S. business that first takes title to imported devices and carries its own importer obligations. FDA U.S. Agents

This matters most for two groups. Startups entering the U.S. for the first time need to avoid assigning a “helpful” service provider to every field without deciding who will actually own registrations, complaints, and importer follow-through. Established manufacturers usually have the opposite problem: multiple distributors, consultants, and affiliates already exist, so the risk is role overlap that nobody explicitly governed. FDA registration and listing instructions

The practical distinction is simple: the U.S. Agent is required because the manufacturer is foreign; the official correspondent is required because someone must manage establishment registration and listing; the initial importer exists only if a U.S. entity is furthering the marketing of the imported device by taking first title in the United States. FDA import guidance

Who this page is for

Foreign device manufacturers setting up FDA registration for the first time
Medtech teams deciding whether a consultant, affiliate, or distributor should be the official correspondent
Manufacturers adding or changing a U.S. distributor and needing to determine whether that party is also the initial importer
Regulatory teams cleaning up role confusion before annual registration renewal, complaint handling, or postmarket events

The role map buyers actually need

Role	What it is	Who appoints it	Where it shows up	What it is responsible for
U.S. Agent	The required U.S.-based contact for a foreign device establishment	The foreign establishment	Foreign establishment registration in FURLS/DRLM	Serving as the FDA contact point for the foreign establishment and supporting communications tied to that registration
Official correspondent	The person designated by the owner/operator to handle establishment registration and device listing communications	The owner/operator of the establishment	FURLS account structure and DRLM registration/listing records	Managing annual registration, listing information, and FDA correspondence involving the owner/operator and assigned establishments
Initial importer	The U.S. importer that furthers marketing by taking first title to an imported device, without repackaging or changing labeling	Not “appointed” in the same way; it is determined by the commercial arrangement	Its own FDA establishment registration and imported-device manufacturer identification	Registering as an initial importer, identifying the manufacturers and devices it imports, and meeting importer postmarket obligations

FDA registration and listing instructions

What the U.S. Agent role does in device registration

For medical devices, each foreign establishment must identify one U.S. Agent as part of establishment registration. The U.S. Agent information is submitted electronically in FURLS, and each foreign establishment may designate only one U.S. Agent. The same entity may also serve as official correspondent, but FDA does not require that structure. FDA U.S. Agents

That last point is where many teams get sloppy. Because the same party can hold both roles, buyers sometimes assume the roles are functionally identical. They are not. The U.S. Agent field answers the question, “Who is the U.S.-based contact for this foreign establishment?” It does not automatically answer, “Who controls the registration workflow, listing maintenance, and account-level correspondence?”

For a startup manufacturer with no U.S. office, using the same compliance partner as both U.S. Agent and official correspondent can be efficient if that partner is also doing the registration and listing work. For a larger manufacturer with internal regulatory staff, separating the roles is often cleaner: the company keeps official-correspondent control while the external U.S. Agent handles the legally required U.S. contact function.

What the official correspondent actually owns

FDA defines the official correspondent as the person designated by the owner/operator who is responsible for annual establishment registration and device listing, and who receives FDA correspondence involving the owner/operator and the firm’s establishments. FDA also notes that if the owner/operator designates another person as official correspondent, the owner/operator must create a separate FURLS subaccount for that person. FDA registration and listing instructions

This is the role with the most operational leverage. If your official correspondent is external, that party often becomes the practical gatekeeper for annual renewals, listing changes, and certain account updates. When teams say “our agent handles everything,” what they usually mean in practice is that the same outside firm is acting as official correspondent and doing the DRLM work.

A pattern worth naming: mailbox thinking breaks here first. A provider can be perfectly willing to receive FDA messages as U.S. Agent and still be a weak choice as official correspondent if they are not set up to manage listing changes, annual registration timing, or the mechanics of DRLM updates. That is why the role decision should be explicit, not inherited from whoever offered the cheapest U.S. address.

Initial importer is not just a contact field

An initial importer is a U.S. entity that furthers the marketing of a device from a foreign manufacturer to the person making final delivery or sale to the ultimate consumer or user, while not repackaging or otherwise changing the container, wrapper, or labeling. In FDA’s registration workflow, initial importers must identify the manufacturers of the devices they are importing and select the imported devices tied to those manufacturers. FDA import guidance

This role is commercial as much as regulatory. You do not choose an initial importer the way you choose a U.S. Agent. The role follows who takes first title and how the U.S. distribution model is structured. If a U.S. distributor buys the product and resells it, that distributor may be the initial importer. If the foreign manufacturer sells directly and another party only acts as customs broker or logistics support, that party may not be the initial importer. FDA who must register and list

That distinction matters because initial importers carry their own FDA obligations. They are not just listed for convenience.

Postmarket responsibilities: where the roles diverge fastest

The cleanest way to understand the split is to ask who owns what after the device is already in market.

Medical Device Reporting (MDR)

Importers have MDR obligations under 21 CFR Part 803. Importers must report deaths and serious injuries to FDA and the manufacturer, and must report certain malfunctions to the manufacturer. Importers also must maintain MDR event files. Foreign manufacturers have their own MDR obligations as manufacturers; the U.S. Agent does not become the manufacturer’s MDR substitute just by being named in registration. FDA MDR guidance

Corrections and removals

Under 21 CFR 806, manufacturers and importers must report certain corrections and removals to FDA when they were initiated to reduce a risk to health or remedy a violative condition that may present a risk to health. FDA also notes that foreign manufacturers and importers should send these reports to the Division Recall Coordinator where the U.S. Agent is located. That means the U.S. Agent’s location can affect the routing of recall-related communications, but the reporting obligation still sits with the manufacturer or importer that initiated the action. FDA corrections and removals

Complaint handling and record access

Complaint files and MDR event files are manufacturer and importer compliance records, not a generic “agent duty.” If an outside party is acting as official correspondent or U.S. Agent, the manufacturer should still decide who maintains complaint intake, who evaluates reportability, and who can produce records quickly if FDA asks. That governance question becomes more important, not less, when roles are outsourced. 21 CFR 820.198

When the same entity can hold more than one role

FDA expressly allows a foreign establishment to designate its U.S. Agent as its official correspondent. In practice, that can work well when one outside regulatory partner is handling registration, listing, and ongoing FDA communications for a smaller foreign manufacturer. FDA U.S. Agents

What should be explicit is why you are combining roles. If the same firm is both U.S. Agent and official correspondent, confirm who controls the FURLS account structure, who submits annual registration, who updates listings after a product change, and how communications are escalated. If the same U.S. distributor is also the initial importer, confirm who owns MDR triage, complaint forwarding, and corrections/removals decision-making.

Combining roles is usually strongest when the workflow is simple and the accountability chain is short. It becomes riskier when the manufacturer has multiple U.S. channels, multiple product families, or internal regulatory staff who assume they still control records that an outside party is actually maintaining.

When a dedicated compliance partner is the stronger fit

FDA Entry Point is built for foreign manufacturers that need a U.S.-based FDA contact plus hands-on registration support across medical devices and other FDA-regulated verticals. FDA Entry Point covers U.S. Agent service, establishment registration, and GUDID/UDI-related support for device work, and it positions itself as a private compliance firm rather than a government portal. FDA Entry Point

That model tends to fit best when the manufacturer does not want a distributor, customs broker, or mailbox-only provider informally absorbing regulatory roles they are not staffed to manage. It is also a practical fit for venture-backed or newly commercial medtech teams that need one accountable outside party for U.S. Agent coverage and registration mechanics while keeping manufacturer obligations clearly assigned. FDA Entry Point device registration page

FDA Entry Point is not a fit when…

The manufacturer already has a mature in-house U.S. regulatory operation and only needs a bare administrative contact
A U.S. affiliate already controls FURLS/DRLM, complaint handling, and importer coordination, and the company does not want an external compliance layer
The buyer is really looking for a commercial importer or distributor relationship rather than a compliance partner

Common mistakes that create avoidable FDA friction

Using one vendor for every field without deciding why. The fact that FDA allows overlap does not mean overlap is automatically well governed.
Assuming the U.S. Agent owns importer duties. MDR, complaint files, and corrections/removals obligations follow the manufacturer and importer roles, not the mailing address on file.
Letting the official correspondent role drift. If nobody clearly owns annual registration and listing maintenance, renewals and updates are where problems usually surface first.
Confusing customs support with initial importer status. A customs broker or forwarding partner is not automatically the initial importer.
Failing to document record access. If an outside party handles submissions or receives FDA communications, the manufacturer should still know how records, acknowledgments, and complaint files are retrieved on demand.

Frequently asked questions

Can the U.S. Agent and official correspondent be the same company for a foreign device manufacturer?

Yes, FDA allows a foreign establishment to designate its U.S. Agent as its official correspondent. The better question is whether that structure matches your operating model: for smaller foreign manufacturers it can simplify accountability, while larger teams often prefer to keep official-correspondent control in-house and use an outside U.S. Agent only for the required U.S. contact role. FDA U.S. Agents

Does a U.S. Agent become the initial importer if they help with FDA registration?

No. Initial importer status depends on the commercial role of the U.S. entity that takes first title and furthers marketing of the imported device, not on who files registration paperwork or serves as U.S. Agent. A compliance firm can be your U.S. Agent and official correspondent without being your initial importer. FDA import guidance

Who handles MDR if a foreign manufacturer appoints an outside U.S. Agent?

The manufacturer and any initial importer keep their own MDR obligations even when an outside U.S. Agent is appointed. Importers must report certain adverse events and maintain MDR event files, while foreign manufacturers remain subject to manufacturer MDR requirements; the U.S. Agent is not a substitute for those regulated responsibilities. FDA MDR guidance

What is the official correspondent actually controlling in FDA systems?

The official correspondent is the person responsible for annual establishment registration and device listing and is the recipient of FDA correspondence involving the owner/operator and assigned establishments. In practice, that means this role often controls the day-to-day registration and listing workflow in FURLS/DRLM. FDA registration and listing instructions

Do startup medtech companies need a separate initial importer on day one?

Not always. A startup only has an initial importer if its U.S. distribution model creates one under FDA’s definition, typically because a U.S. entity takes first title and furthers marketing of the imported device. If the company is still pre-commercial or has not finalized its U.S. channel structure, the right answer is to map the commercial flow before assigning the role. FDA who must register and list